6 research outputs found
Where is the 'global' in the European Union's Health Research and Innovation Agenda?
Global Health has not featured as prominently in the
European Union (EU) research agenda in recent years as it did in
the first decade of the new millennium, and participation of
low-income and middle-income countries (LMICs) in EU health
research has declined substantially. The Horizon Europe Research
and Innovation Framework adopted by the European Parliament in
April 2019 for the period 2021-2027 will serve as an important
funding instrument for health research, yet the proposed health
research budget to be finalised towards the end of 2019 was
reduced from 10% in the current framework, Horizon 2020, to 8%
in Horizon Europe. Our analysis takes the evolvement of Horizon
Europe from the initial framework of June 2018 to the framework
agreed on in April 2019 into account. It shows that despite some
improvements in terms of Global Health and reference to the
Sustainable Development Goals, European industrial
competitiveness continues to play a paramount role, with Global
Health research needs and relevant health research for LMICs
being only partially addressed. We argue that the globally
interconnected nature of health and the transdisciplinary nature
of health research need to be fully taken into account and acted
on in the new European Research and Innovation Framework. A
facilitated global research collaboration through Horizon Europe
could ensure that Global Health innovations and solutions
benefit all parts of the world including EU countries
APC/CCdh1-Mediated Degradation of the F-Box Protein NIPA Is Regulated by Its Association with Skp1
NIPA (Nuclear Interaction Partner of Alk kinase) is an F-box like protein
that targets nuclear Cyclin B1 for degradation. Integrity and therefore activity
of the SCFNIPA E3 ligase is regulated by cell-cycle-dependent phosphorylation
of NIPA, restricting substrate ubiquitination to interphase. Here we show
that phosphorylated NIPA is degraded in late mitosis in an APC/CCdh1-dependent
manner. Binding of the unphosphorylated form of NIPA to Skp1 interferes with
binding to the APC/C-adaptor protein Cdh1 and therefore protects unphosphorylated
NIPA from degradation in interphase. Our data thus define a novel mode of
regulating APC/C-mediated ubiquitination
Where is the 'global' in the European Union's Health Research and Innovation Agenda?
Global Health has not featured as prominently in the
European Union (EU) research agenda in recent years as it did in
the first decade of the new millennium, and participation of
low-income and middle-income countries (LMICs) in EU health
research has declined substantially. The Horizon Europe Research
and Innovation Framework adopted by the European Parliament in
April 2019 for the period 2021-2027 will serve as an important
funding instrument for health research, yet the proposed health
research budget to be finalised towards the end of 2019 was
reduced from 10% in the current framework, Horizon 2020, to 8%
in Horizon Europe. Our analysis takes the evolvement of Horizon
Europe from the initial framework of June 2018 to the framework
agreed on in April 2019 into account. It shows that despite some
improvements in terms of Global Health and reference to the
Sustainable Development Goals, European industrial
competitiveness continues to play a paramount role, with Global
Health research needs and relevant health research for LMICs
being only partially addressed. We argue that the globally
interconnected nature of health and the transdisciplinary nature
of health research need to be fully taken into account and acted
on in the new European Research and Innovation Framework. A
facilitated global research collaboration through Horizon Europe
could ensure that Global Health innovations and solutions
benefit all parts of the world including EU countries
A highly virulent variant of HIV-1 circulating in the Netherlands
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence